Pharmacy benefit managers, known as PBMs, have unexpectedly united Republicans and Democrats as patients and lawmakers target the healthcare middlemen for driving up prescription drug costs and limiting local pharmacy choices. As reported by NPR, Tennessee and Arkansas are leading a growing legislative push to regulate these companies.
PBM Consolidation Draws Intense Public Scrutiny
Pharmacy benefit managers handle the administration of prescription drug benefits within health insurance plans. Originally established to negotiate lower drug prices with manufacturers and manage prescription claims, the largest PBMs have evolved significantly over time. Conglomerates such as CVS Health now own insurance companies like Aetna, dominant PBMs like CVS Caremark, and massive retail pharmacy chains.
This deep market consolidation has drawn intense public scrutiny. Patients and independent pharmacists argue that PBMs have transformed from cost-saving intermediaries into profit-generating entities. Amye Joseph, a 62-year-old resident of eastern Tennessee, voiced a common frustration shared across the political spectrum. “We hate CVS. I’m going to be straight-up,” Amye Joseph said, pointing to overstressed pharmacists and a lack of transparency in drug pricing.
Her husband, Charlie Joseph, a retired fire captain and custodian, discovered firsthand how the system can penalize consumers. He realized his blood pressure medication was substantially cheaper when he bypassed his CVS Caremark insurance plan and paid cash directly at his local pharmacy. Charlie Joseph now purchases a 90-day supply for the exact price a 30-day supply would have cost through his insurance plan.
Legislative Pushback and Bipartisan Alignment in Tennessee
State lawmakers are increasingly challenging the defense offered by PBM executives. Dave Marin, president and CEO of the Pharmaceutical Care Management Association, defended the industry before Congress in February, asserting that drug prices would be much higher without PBM involvement. However, state legislatures remain skeptical of these arguments.
Tennessee became one of two states to pass legislation making it illegal for a single company to own both a PBM and retail brick-and-mortar pharmacies. CVS Health launched a multimillion-dollar television advertising campaign warning that 134 CVS pharmacies across Tennessee could shut down, compromising healthcare access. Despite the heavy lobbying and ads airing just before the vote, Tennessee lawmakers advanced the measure.
Business-friendly conservatives voted alongside Democrats who favor stricter market oversight. State Representative Antonio Parkinson, a Democrat from Memphis, noted that he supported the measure to protect lower drug prices and independent community pharmacies.
Independent Pharmacies Fuel the Federal and State Debate
The legislative momentum against PBMs draws strong backing from independent pharmacists and their trade associations. In Tennessee, legislative figures like State Senator Bobby Harshbarger—himself a small-town pharmacist—championed the ownership ban. Harshbarger’s mother, a pharmacist and a member of the U.S. Congress, has proposed parallel federal legislation to ban PBMs from owning pharmacies nationwide. That federal bill has bridged traditional partisan divides by uniting unlikely political bedfellows such as Senators Elizabeth Warren and Josh Hawley.
Antonio Ciaccia, CEO of 46brooklyn Research, a nonprofit think tank tracking drug pricing, noted that this conservative participation reflects a deeper ideological shift. Republicans increasingly recognize that standard market competition is failing in the pharmaceutical sector. Ciaccia stated that Republicans are observing the market and realizing it functions as a “free-for-all” rather than a free market.
CVS Warns State Laws Will Increase Drug Prices
In response to the new regulations, CVS issued a statement maintaining that the state laws will produce the exact opposite of their intended effect and ultimately drive up prescription prices. Legal analysts remain uncertain whether state-level bans prohibiting PBMs from owning pharmacies will withstand anticipated court challenges, or whether major conglomerates like CVS will ultimately proceed with closing retail locations. Regardless of judicial outcomes, PBMs face unprecedented political friction in both state and federal governments.
References
- KFF Health News: Republicans and Democrats Find a Unifying Target
- National Public Radio (NPR): Healthcare Common Ground Project
- 46brooklyn Research: Prescription Drug Pricing and Market Transparency Data
